Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended 6 Months Ended 107 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Consolidated Statements Of Operations          
Revenues              
Total revenues               
Operating expenses:          
Amortization & depreciation 194    388 152 76,737
General and administrative 148,897 145,699 382,538 2,031,147 12,950,487
Total operating expenses 149,091 145,699 382,926 2,031,299 13,027,224
Gain (loss) from operations (149,091) (145,699) (382,926) (2,031,299) (13,027,224)
Other income (expense):          
Loss on fair value adjustment - derivatives (293,684)    (389,297)    (837,434)
Stock option expense (80,953)    (80,953)    (80,953)
Gain on debt reversal       5,571    5,571
Gain on sale of fixed asset        4,790 4,790
Interest expense (25,657) (20,777) (66,057) (35,212) (1,159,049)
Interest expense - beneficial conversion feature (56,389) (44,035) (133,492) (20,136) (315,556)
Total other income (expense) (456,683) (64,812) (664,228) (50,558) (2,382,631)
Income (loss) before provision for income taxes (605,774) (210,511) (1,047,154) (2,081,857) (15,409,855)
Provision for income tax               
Net income (loss) (605,774) (210,511) (1,047,154) (2,081,857) (15,409,855)
Less: Net (income) loss attributable to noncontrolling interest 2,280 2,095 5,185 3,246 93,642
Net income (loss) attributable to TransBiotec, Inc. $ (603,494) $ (208,416) $ (1,041,969) $ (2,078,611) $ (15,316,213)
Net income (loss) per share (TransBiotec, Inc.)          
(Basic and fully diluted) $ (0.02) $ (0.01) $ (0.03) $ (0.08)  
Weighted average number of common shares outstanding 31,796,478 28,007,094 31,291,992 25,496,925